Raymond James raised Johnson & Johnson's price target to $280, signaling a 10% upside from current levels. The boost follows strong Q2 revenue growth in its oncology division, which now accounts for nearly 29% of total revenues, driven by key cancer therapies. Positive analyst sentiment and the upcoming launch of the OTTAVA robotic surgical system highlight the company's growth potential and innovation in healthcare technology.
Five established companies—Johnson & Johnson, PepsiCo, Coca-Cola, Exxon Mobil, and Kimberly-Clark—have declared new dividends backed by decades of consistent payout increases. Each company recently reported strong earnings or raised guidance, signali...
Johnson & Johnson's stock reached $270.24, close to its 52-week high of $276.47, following raised full-year guidance and FDA approval of a new robotic surgical system. The company shows strong growth in oncology and immunology, with key products like...
Jim Cramer highlighted a market rotation away from tech and data center stocks toward enterprise software and pharmaceuticals, driven by political opposition to data center construction and bond market volatility. Software companies like ServiceNow, ...
With the 10-Year Treasury yield at 4.74%, dividend stocks must offer durable income. Dividend Aristocrats, companies with 25+ years of dividend increases, remain reliable for retirement income. Coca-Cola, Procter & Gamble, Johnson & Johnson, PepsiCo,...
The FDA has approved IMAAVY (nipocalimab-aahu) for treating warm autoimmune hemolytic anemia (wAIHA) in patients aged 12 and older, marking the first therapy specifically proven safe and effective for this rare, life-threatening disease. IMAAVY works...
